Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report.
Fiche publication
Date publication
février 2016
Journal
Journal of clinical pharmacy and therapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LIOURE Bruno
Tous les auteurs :
Lambert Kuhn E, Levêque D, Lioure B, Gourieux B, Bilbault P
Lien Pubmed
Résumé
Ibrutinib is a recently approved oral anticancer agent with pharmacokinetics that is very sensitive to metabolic inhibition. We report a serious side effect of ibrutinib potentially attributable to interaction with the moderate CYP3A4 inhibitor verapamil.
Mots clés
Aged, Antihypertensive Agents, administration & dosage, Antineoplastic Agents, administration & dosage, Cytochrome P-450 CYP3A Inhibitors, administration & dosage, Diarrhea, chemically induced, Dihydropyridines, administration & dosage, Drug Interactions, Humans, Lymphoma, Mantle-Cell, drug therapy, Male, Pyrazoles, administration & dosage, Pyrimidines, administration & dosage, Verapamil, administration & dosage
Référence
J Clin Pharm Ther. 2016 Feb;41(1):104-5